Erin K. Brenner - 14 Jan 2023 Form 4 Insider Report for Pear Therapeutics, Inc.

Role: Chief Product Dev. Officer
Signature: /s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Jan 2023, 17:42:39 UTC
Previous filing: 09 Dec 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PEARQ	Common Stock	Options Exercise	$0	+22,000	+73%	$0.000000	52,000	14 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PEARQ	Restricted Stock Units	Options Exercise	$0	-22,000	-33%	$0.000000	44,667	14 Jan 2023	Common Stock	22,000		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F2	The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.